Award-Winning Innovation: MBrace was shortlisted "Best New Drug Developer" and awarded "Most Promising Clinical Candidate for MBRC-101" at the 11th Annual World ADC Awards

New Targets
New Treatments
New Possibilities

Learn about MBRC-201 antibody drug conjugate development and ways patients may qualify to participate in our clinical trial.

Our Phase 1/2 study in solid tumors

MBRC-201-001

A Multicenter, Open-Label Phase 1/2 Dose-Finding, Safety, and Pharma Cokinetic Study Of MBRC-201, An Antibody-Drug Conjugate In Advanced Refractory Solid Tumors

Now Enrolling

This is a first-in-human, open-label, Phase 1/2 study in patients with advanced metastatic solid tumors refractory to standard treatment, including metastatic castration-resistant prostate cancer (mCRPC), breast cancer, colorectal cancer (CRC), pancreatic cancer, and non-small cell lung cancer (NSCLC).

Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-201 at one or more dosing regimens.

Phase 1b will evaluate the safety and preliminary activity of MBRC-201 at clinically relevant doses in mCRPC, breast cancer, NSCLC and other solid tumors. Phase 1 and Phase 1b will characterize single and multiple-dose pharmacokinetics profiles of MBRC-201.

The initial Phase 2 will further evaluate antitumor activity and safety of MBRC-201 at the RP2D determined during Phase 1b. Phase 2 will enroll patients in tumor-specific cohorts from the indications evaluated in Phase 1a/1b.

For more information about the MBRC-201-001 clinical trial, and to review patient eligibility criteria, visit clinicaltrials.gov (identifier NCT07145255).

If you are a physician interested in more information, please contact: clinicalsupport@mbracetrx.com.

MBrace’s Expanded Access Policy

Additional resources

See what makes our antibody and drug target discovery methods unique.

Learn about the antibody-drug conjugates in our development pipeline.

Additional resources

See what makes our antibody and drug target discovery methods unique.

Learn about the antibody-drug conjugates in our development pipeline.

For clinical trial inquiries, please contact us at:

For more information about MBrace’s products or programs please contact us at: